Restructuring	12 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring On August 20, 2024, the Company announced a reduction in force plan (the “Plan”) as part of its broader efforts to drive balanced, profitable growth, further supporting its positive, long-term outlook and focus on increasing shareholder value. The Plan reduced the Company’s global full-time employees by approximately 6%. For the year ended December 31, 2024, the Company incurred a total of $9.6 million in restructuring costs under the Plan, primarily consisting of notice period payments, severance payments, employee benefits and related costs, all of which are cash expenditures, of which $2.1 million was recorded in cost of revenue, $1.9 million was recorded in research and development expenses, $4.4 million was recorded in sales and marketing expenses, and $1.2 million was recorded in general and administrative expenses on the consolidated statements of operations and comprehensive loss. As of December 31, 2024, $9.3 million had been paid and the remaining $0.3 million was recorded within Accrued and other current liabilities in the consolidated balance sheets and is mostly expected to be paid by the first quarter of 2025. Other than as set forth herein, the Company does not expect to incur any additional costs under the Plan.

Restructuring

12 Months Ended

Dec. 31, 2024

Restructuring and Related Activities [Abstract]

On August 20, 2024, the Company announced a reduction in force plan (the “Plan”) as part of its broader efforts to drive balanced, profitable growth, further supporting its positive, long-term outlook and focus on increasing shareholder value. The Plan reduced the Company’s global full-time employees by approximately 6%. For the year ended December 31, 2024, the Company incurred a total of $9.6 million in restructuring costs under the Plan, primarily consisting of notice period payments, severance payments, employee benefits and related costs, all of which are cash expenditures, of which $2.1 million was recorded in cost of revenue, $1.9 million was recorded in research and development expenses, $4.4 million was recorded in sales and marketing expenses, and $1.2 million was recorded in general and administrative expenses on the consolidated statements of operations and comprehensive loss. As of December 31, 2024, $9.3 million had been paid and the remaining $0.3 million was recorded within Accrued and other current liabilities in the consolidated balance sheets and is mostly expected to be paid by the first quarter of 2025. Other than as set forth herein, the Company does not expect to incur any additional costs under the Plan.